Paper Details

  1. Home
  2. Paper Details

Improved Outcomes of All-trans-retinoic Acid and Arsenic Trioxide Plus Idarubicin as a Frontline Treatment in Adult Patients With Acute Promyelocytic Leukemia.

Author: ChenXiangli, GuoJianmin, JiangLi, LeiPingchong, LiuZhongwen, MaRongjun, ShiJie, YangJing, YangShiwei, YuanXiaoli, ZangYuzhu, ZhangLin, ZhangYin, ZhuXiaojian, ZhuZunmin

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

A retrospective analysis of 118 adult patients with acute promyelocytic leukemia (APL) found that a triple combination of all-trans-retinoic acid (ATRA), arsenic trioxide (ATO), and idarubicin (IDA) as frontline induction and consolidation therapy achieved excellent outcomes, with a 5-year overall survival (OS) of 93.0% and event-free survival (EFS) of 92.4%. This regimen may be a preferred frontline therapy for APL, especially for high-risk patients or those with the APL fms-related tyrosine kinase 3 internal tandem duplication mutation.
Paper Details　
Original Abstract of the Article :
INTRODUCTION: The purpose of this study was to explore the outcomes of all-trans-retinoic acid (ATRA) and arsenic trioxide (ATO) plus idarubicin (IDA) as a frontline treatment in adult patients with acute promyelocytic leukemia (APL). PATIENTS AND METHODS: We analyzed the outcomes of ATRA and intra...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.clml.2019.10.003

データ提供：米国国立医学図書館（NLM）

Triple Combination Therapy: A Promising Frontline Treatment for Acute Promyelocytic Leukemia

The field of [acute promyelocytic leukemia (APL) treatment] is constantly evolving to improve outcomes for patients. This study investigates the efficacy of a [triple combination therapy] using [all-trans-retinoic acid (ATRA), arsenic trioxide (ATO), and idarubicin (IDA)] as a frontline treatment for APL. The researchers analyzed the outcomes of this regimen in a cohort of adult patients with APL, assessing hematologic complete remission (HCR), molecular complete remission (MCR), and overall survival (OS). Their findings revealed that the triple combination therapy achieved excellent outcomes, with high rates of HCR and MCR, and favorable OS. The study provides compelling evidence for the potential of this regimen to significantly improve treatment outcomes for APL patients.

Triple Combination Therapy Shows Excellent Outcomes in Treating Acute Promyelocytic Leukemia

The study’s results demonstrate the [efficacy and safety] of the [triple combination therapy] in achieving high rates of [hematologic complete remission and molecular complete remission] in patients with [acute promyelocytic leukemia]. The favorable overall survival rates observed in this study suggest that this regimen could become a preferred frontline therapy for APL patients.

New Hope for APL Patients and Future Directions in Treatment

This research offers encouraging news for [patients with acute promyelocytic leukemia]. The study’s findings highlight the potential of [triple combination therapy] to significantly improve [treatment outcomes]. Further research is needed to fully understand the long-term effects of this regimen and its potential for different patient subgroups. However, the study provides a promising foundation for developing more effective and personalized treatment approaches for APL.

Dr.Camel's Conclusion

Like a camel carrying essential supplies across the desert, this study delivers promising news for those battling acute promyelocytic leukemia. The triple combination therapy shows significant potential for improving treatment outcomes, offering hope for a brighter future for APL patients.

Date :
  1. Date Completed 2021-08-25
  2. Date Revised 2021-08-25
Further Info :

Pubmed ID

32336675

DOI: Digital Object Identifier

10.1016/j.clml.2019.10.003

Related Literature

Article Analysis
・Side Effects of idarubicin
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.